FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Disturbed sleep is a prominent feature of fibromyalgia symptomatology and has been proposed as one of the core symptoms that should be systematically assessed in clinical trials for the treatment ...

Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.

A mum-of-two is praising a miraculous new form of magnetic treatment that has given her life back after more than a decade of ...

New research has identified cannabis-derived terpenes—compounds that give plants their distinctive aroma—as effective ...

Tonix Pharmaceuticals (NASDAQ:TNXP) just lit up the market, surging as much as 41% before pulling back to a 17% gain at 1.24pm today. The catalyst? Fresh Phase 3 trial data for its fibromyalgia ...

A recently completed study found that certain terpenes in Cannabis sativa are effective at relieving post-surgical and fibromyalgia pain in preclinical models.

Background: Although trazodone is frequently used by fibromyalgia patients, its efficacy on this disease has not been adequately studied. If effective, pregabalin, whose beneficial effects on pain ...

Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of ...

Baylor Medicine offers the Graston Technique® for injury treatment and rehabilitation. This remarkable procedure allows us to detect and treat areas of “scar tissue” or adhesions in muscles, tendons ...

Terpenes from the Cannabis sativa plant may be a viable medication for fibromyalgia and post-surgical pain relief, according to ...